Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI)
To re-examine the use of noncarbapenems (NCBPs), specifically piperacillin-tazobactam (PTZ) and cefepime (FEP), for extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (ESBL-E BSIs). Retrospective cohort study. Tertiary-care, academic medical center. The study included...
Saved in:
| Published in: | Antimicrobial stewardship & healthcare epidemiology : ASHE Vol. 2; no. 1; p. e39 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
Cambridge University Press
2022
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | To re-examine the use of noncarbapenems (NCBPs), specifically piperacillin-tazobactam (PTZ) and cefepime (FEP), for extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (ESBL-E BSIs).
Retrospective cohort study.
Tertiary-care, academic medical center.
The study included patients hospitalized between May 2016 and May 2019 with a positive blood culture for ESBL-E. Patients were excluded if they received treatment with antibiotics other than meropenem, ertapenem, PTZ, or FEP. Patients were also excluded if they were aged <18 years, received antibiotics for <24 hours, were treated for polymicrobial BSI, or received concomitant antibiotic therapy for a separate gram-negative infection.
We compared CBPs with FEP or PTZ for the treatment of ESBL-E BSI. The primary outcome was in-hospital mortality. Secondary outcomes included clinical cure, microbiologic cure, infection recurrence, and resistance development.
Data from 114 patients were collected and analyzed; 74 (65%) patients received carbapenem (CBP) therapy and 40 (35%) patients received a NCBP (30 received FEP and 10 received PTZ). The overall in-hospital mortality was 6% (N = 7), with a higher death rate in the CBP arm than in the N-CBP arm, (8% vs 3%;
= .42). No difference in mortality was detected between subgroups with Pitt bacteremia score ≥4, those requiring ICU admission, those whose infections were cause by a nongenitourinary source or causative organism (ie, 76 had
and 38 had
spp). We detected no differences in secondary outcomes between the groups.
Compared to CBPs, FEP and PTZ did not result in greater mortality or decreased clinical efficacy for the treatment of ESBL-E BSI caused by susceptible organisms. |
|---|---|
| AbstractList | To re-examine the use of noncarbapenems (NCBPs), specifically piperacillin-tazobactam (PTZ) and cefepime (FEP), for extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (ESBL-E BSIs).ObjectiveTo re-examine the use of noncarbapenems (NCBPs), specifically piperacillin-tazobactam (PTZ) and cefepime (FEP), for extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (ESBL-E BSIs).Retrospective cohort study.DesignRetrospective cohort study.Tertiary-care, academic medical center.SettingTertiary-care, academic medical center.The study included patients hospitalized between May 2016 and May 2019 with a positive blood culture for ESBL-E. Patients were excluded if they received treatment with antibiotics other than meropenem, ertapenem, PTZ, or FEP. Patients were also excluded if they were aged <18 years, received antibiotics for <24 hours, were treated for polymicrobial BSI, or received concomitant antibiotic therapy for a separate gram-negative infection.PatientsThe study included patients hospitalized between May 2016 and May 2019 with a positive blood culture for ESBL-E. Patients were excluded if they received treatment with antibiotics other than meropenem, ertapenem, PTZ, or FEP. Patients were also excluded if they were aged <18 years, received antibiotics for <24 hours, were treated for polymicrobial BSI, or received concomitant antibiotic therapy for a separate gram-negative infection.We compared CBPs with FEP or PTZ for the treatment of ESBL-E BSI. The primary outcome was in-hospital mortality. Secondary outcomes included clinical cure, microbiologic cure, infection recurrence, and resistance development.MethodsWe compared CBPs with FEP or PTZ for the treatment of ESBL-E BSI. The primary outcome was in-hospital mortality. Secondary outcomes included clinical cure, microbiologic cure, infection recurrence, and resistance development.Data from 114 patients were collected and analyzed; 74 (65%) patients received carbapenem (CBP) therapy and 40 (35%) patients received a NCBP (30 received FEP and 10 received PTZ). The overall in-hospital mortality was 6% (N = 7), with a higher death rate in the CBP arm than in the N-CBP arm, (8% vs 3%; P = .42). No difference in mortality was detected between subgroups with Pitt bacteremia score ≥4, those requiring ICU admission, those whose infections were cause by a nongenitourinary source or causative organism (ie, 76 had Escherichia coli and 38 had Klebsiella spp). We detected no differences in secondary outcomes between the groups.ResultsData from 114 patients were collected and analyzed; 74 (65%) patients received carbapenem (CBP) therapy and 40 (35%) patients received a NCBP (30 received FEP and 10 received PTZ). The overall in-hospital mortality was 6% (N = 7), with a higher death rate in the CBP arm than in the N-CBP arm, (8% vs 3%; P = .42). No difference in mortality was detected between subgroups with Pitt bacteremia score ≥4, those requiring ICU admission, those whose infections were cause by a nongenitourinary source or causative organism (ie, 76 had Escherichia coli and 38 had Klebsiella spp). We detected no differences in secondary outcomes between the groups.Compared to CBPs, FEP and PTZ did not result in greater mortality or decreased clinical efficacy for the treatment of ESBL-E BSI caused by susceptible organisms.ConclusionCompared to CBPs, FEP and PTZ did not result in greater mortality or decreased clinical efficacy for the treatment of ESBL-E BSI caused by susceptible organisms. To re-examine the use of noncarbapenems (NCBPs), specifically piperacillin-tazobactam (PTZ) and cefepime (FEP), for extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (ESBL-E BSIs). Retrospective cohort study. Tertiary-care, academic medical center. The study included patients hospitalized between May 2016 and May 2019 with a positive blood culture for ESBL-E. Patients were excluded if they received treatment with antibiotics other than meropenem, ertapenem, PTZ, or FEP. Patients were also excluded if they were aged <18 years, received antibiotics for <24 hours, were treated for polymicrobial BSI, or received concomitant antibiotic therapy for a separate gram-negative infection. We compared CBPs with FEP or PTZ for the treatment of ESBL-E BSI. The primary outcome was in-hospital mortality. Secondary outcomes included clinical cure, microbiologic cure, infection recurrence, and resistance development. Data from 114 patients were collected and analyzed; 74 (65%) patients received carbapenem (CBP) therapy and 40 (35%) patients received a NCBP (30 received FEP and 10 received PTZ). The overall in-hospital mortality was 6% (N = 7), with a higher death rate in the CBP arm than in the N-CBP arm, (8% vs 3%; = .42). No difference in mortality was detected between subgroups with Pitt bacteremia score ≥4, those requiring ICU admission, those whose infections were cause by a nongenitourinary source or causative organism (ie, 76 had and 38 had spp). We detected no differences in secondary outcomes between the groups. Compared to CBPs, FEP and PTZ did not result in greater mortality or decreased clinical efficacy for the treatment of ESBL-E BSI caused by susceptible organisms. Abstract Objective: To re-examine the use of noncarbapenems (NCBPs), specifically piperacillin-tazobactam (PTZ) and cefepime (FEP), for extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (ESBL-E BSIs). Design: Retrospective cohort study. Setting: Tertiary-care, academic medical center. Patients: The study included patients hospitalized between May 2016 and May 2019 with a positive blood culture for ESBL-E. Patients were excluded if they received treatment with antibiotics other than meropenem, ertapenem, PTZ, or FEP. Patients were also excluded if they were aged <18 years, received antibiotics for <24 hours, were treated for polymicrobial BSI, or received concomitant antibiotic therapy for a separate gram-negative infection. Methods: We compared CBPs with FEP or PTZ for the treatment of ESBL-E BSI. The primary outcome was in-hospital mortality. Secondary outcomes included clinical cure, microbiologic cure, infection recurrence, and resistance development. Results: Data from 114 patients were collected and analyzed; 74 (65%) patients received carbapenem (CBP) therapy and 40 (35%) patients received a NCBP (30 received FEP and 10 received PTZ). The overall in-hospital mortality was 6% (N = 7), with a higher death rate in the CBP arm than in the N-CBP arm, (8% vs 3%; P = .42). No difference in mortality was detected between subgroups with Pitt bacteremia score ≥4, those requiring ICU admission, those whose infections were cause by a nongenitourinary source or causative organism (ie, 76 had Escherichia coli and 38 had Klebsiella spp). We detected no differences in secondary outcomes between the groups. Conclusion: Compared to CBPs, FEP and PTZ did not result in greater mortality or decreased clinical efficacy for the treatment of ESBL-E BSI caused by susceptible organisms. Abstract Objective: To re-examine the use of noncarbapenems (NCBPs), specifically piperacillin-tazobactam (PTZ) and cefepime (FEP), for extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (ESBL-E BSIs). Design: Retrospective cohort study. Setting: Tertiary-care, academic medical center. Patients: The study included patients hospitalized between May 2016 and May 2019 with a positive blood culture for ESBL-E. Patients were excluded if they received treatment with antibiotics other than meropenem, ertapenem, PTZ, or FEP. Patients were also excluded if they were aged <18 years, received antibiotics for <24 hours, were treated for polymicrobial BSI, or received concomitant antibiotic therapy for a separate gram-negative infection. Methods: We compared CBPs with FEP or PTZ for the treatment of ESBL-E BSI. The primary outcome was in-hospital mortality. Secondary outcomes included clinical cure, microbiologic cure, infection recurrence, and resistance development. Results: Data from 114 patients were collected and analyzed; 74 (65%) patients received carbapenem (CBP) therapy and 40 (35%) patients received a NCBP (30 received FEP and 10 received PTZ). The overall in-hospital mortality was 6% (N = 7), with a higher death rate in the CBP arm than in the N-CBP arm, (8% vs 3%; P = .42). No difference in mortality was detected between subgroups with Pitt bacteremia score ≥4, those requiring ICU admission, those whose infections were cause by a nongenitourinary source or causative organism (ie, 76 had Escherichia coli and 38 had Klebsiella spp). We detected no differences in secondary outcomes between the groups. Conclusion: Compared to CBPs, FEP and PTZ did not result in greater mortality or decreased clinical efficacy for the treatment of ESBL-E BSI caused by susceptible organisms. |
| ArticleNumber | e39 |
| Author | Venugopalan, Veena Santevecchi, Barbara A Voils, Stacy A Ramphal, Reuben Vu, Catherine H Cherabuddi, Kartikeya DeSear, Kathryn |
| AuthorAffiliation | 2 Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy , Gainesville , Florida 3 Department of Medicine, College of Medicine, University of Florida , Gainesville , Florida 4 Department of Pharmacy, University of Florida Health Shands Hospital , Gainesville , Florida 1 Department of Pharmacy , University Medical Center New Orleans, New Orleans , Louisiana |
| AuthorAffiliation_xml | – name: 3 Department of Medicine, College of Medicine, University of Florida , Gainesville , Florida – name: 2 Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy , Gainesville , Florida – name: 4 Department of Pharmacy, University of Florida Health Shands Hospital , Gainesville , Florida – name: 1 Department of Pharmacy , University Medical Center New Orleans, New Orleans , Louisiana |
| Author_xml | – sequence: 1 givenname: Catherine H surname: Vu fullname: Vu, Catherine H organization: Department of Pharmacy, University Medical Center New Orleans, New Orleans, Louisiana – sequence: 2 givenname: Veena orcidid: 0000-0002-9424-5783 surname: Venugopalan fullname: Venugopalan, Veena organization: Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida – sequence: 3 givenname: Barbara A orcidid: 0000-0001-5239-8303 surname: Santevecchi fullname: Santevecchi, Barbara A organization: Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida – sequence: 4 givenname: Stacy A orcidid: 0000-0002-6741-5249 surname: Voils fullname: Voils, Stacy A organization: Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida – sequence: 5 givenname: Reuben orcidid: 0000-0002-9087-1816 surname: Ramphal fullname: Ramphal, Reuben organization: Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida – sequence: 6 givenname: Kartikeya surname: Cherabuddi fullname: Cherabuddi, Kartikeya organization: Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida – sequence: 7 givenname: Kathryn orcidid: 0000-0002-9042-9075 surname: DeSear fullname: DeSear, Kathryn organization: Department of Pharmacy, University of Florida Health Shands Hospital, Gainesville, Florida |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36310806$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkt9rFDEQx4NUbK198l3yWJE9k2xuf7wIep56UBCqBd_CbHb2mpJN1iRb1D_Mv8_cXS0tJCQk8_3MDPN9To6cd0jIS84WnPH6LcTrhWBCLAR_Qk5EXYpCtvLH0YP7MTmL8YYxJhrO6rZ-Ro7LquSsYdUJ-XuJBd6CnSEZ76gfqMYBJzMi9YFOZsIA2lhrXJHgj-9AJxhp8rRHHRAi0jnvnQxCBxM6HCM1juKvhK7HvogT6hTmkXaYoLB7fZYVU_D9rI3b0rVLGPbknMtipJ31vo8p48eMGrI-lxbp-eX649VqXXz4tnn9gjwdwEY8uztPydWn9ffVl-Li6-fN6v1FoaWsUwFsELqWFWskY0PbLZei5i2WXaMlbyD3UPbIOiE07zQ0iCh1W3XQymqJsq3LU7I5cHsPN2oKZoTwW3kwav_gw1ZBSEZbVIPsGzbwijeslyBrGDQr2X7JWgieWe8OrGnuRuw1upT7fQR9_OPMtdr6W9VWfJlHnAHnd4Dgf84YkxpN1GgtOPRzVHnirJKVLJsc-uYQqoOPMeBwn4YztTOOysZRO-OofWWvHlZ2H_vfJuU_a3DEnQ |
| CitedBy_id | crossref_primary_10_1016_j_ejps_2022_106334 crossref_primary_10_1093_jacamr_dlad021 crossref_primary_10_3390_pharmacy11020074 crossref_primary_10_25259_JLP_2023_4_29__1769 crossref_primary_10_1186_s13613_023_01134_9 crossref_primary_10_1016_S1473_3099_24_00149_X crossref_primary_10_2217_fmb_2022_0097 |
| Cites_doi | 10.1128/AAC.00365-16 10.1093/jac/dkl349 10.1016/j.ijantimicag.2018.07.021 10.1093/cid/ciaa1479 10.1093/jac/dky168 10.1001/jama.2018.12163 10.1016/j.ijantimicag.2005.06.004 10.1128/AAC.00164-17 10.1093/cid/cir790 10.1093/ofid/ofy347 10.1128/AAC.01477-15 10.1016/j.cmi.2019.03.030 10.1093/cid/cit017 10.1128/AAC.05419-11 10.1093/cid/cis916 10.1128/AAC.00355-19 10.1177/0897190017743134 10.1093/ofid/ofw132 10.1093/infdis/jiw282 10.3390/antibiotics9020061 10.1128/AAC.01813-18 10.1128/AAC.48.6.1941-1947.2004 10.1093/cid/cix034 10.1128/JCM.02128-16 10.1007/s10096-017-3133-2 10.1128/JCM.02424-15 10.1111/j.1469-0691.2005.01265.x |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022. The Author(s) 2022 2022 The Author(s) |
| Copyright_xml | – notice: The Author(s) 2022. – notice: The Author(s) 2022 2022 The Author(s) |
| DBID | NPM AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.1017/ash.2022.21 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| EISSN | 2732-494X |
| ExternalDocumentID | oai_doaj_org_article_f4d80f16180d4a47afc0300300347221 10_1017_ash_2022_21 36310806 |
| Genre | Journal Article |
| GroupedDBID | 09C 09E 0R~ 7RV 7X7 8C1 8FI 8FJ AASVR ABUWG ABVZP ADAZD ADDNB ADKIL ADVJH AEBAK AEYHU AFKRA AGABE AGJUD AHIPN AHRGI ALIPV ALMA_UNASSIGNED_HOLDINGS AQJOH BENPR BLZWO CCPQU CCQAD CJCSC FYUFA GROUPED_DOAJ HMCUK IKXGN IPYYG M0T M~E NAPCQ NPM OK1 PGMZT PIMPY RCA ROL RPM UKHRP WFFJZ AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c447t-a0f2c74608400f9b552719e3b8c418adec3de0b22c1bca8eee4c96ba9465e4973 |
| IEDL.DBID | RPM |
| ISSN | 2732-494X |
| IngestDate | Tue Oct 22 15:15:39 EDT 2024 Tue Sep 17 21:31:05 EDT 2024 Sat Oct 26 04:13:14 EDT 2024 Fri Aug 23 02:05:46 EDT 2024 Sat Nov 02 12:23:58 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | The Author(s) 2022. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided that no alterations are made and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use and/or adaptation of the article. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c447t-a0f2c74608400f9b552719e3b8c418adec3de0b22c1bca8eee4c96ba9465e4973 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-9087-1816 0000-0002-6741-5249 0000-0002-9424-5783 0000-0001-5239-8303 0000-0002-9042-9075 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615022/ |
| PMID | 36310806 |
| PQID | 2730646438 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f4d80f16180d4a47afc0300300347221 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9615022 proquest_miscellaneous_2730646438 crossref_primary_10_1017_ash_2022_21 pubmed_primary_36310806 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-00-00 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – year: 2022 text: 2022-00-00 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: New York, USA |
| PublicationTitle | Antimicrobial stewardship & healthcare epidemiology : ASHE |
| PublicationTitleAlternate | Antimicrob Steward Healthc Epidemiol |
| PublicationYear | 2022 |
| Publisher | Cambridge University Press |
| Publisher_xml | – name: Cambridge University Press |
| References | S2732494X22000213_ref26 Roos (S2732494X22000213_ref29) 2006; 58 S2732494X22000213_ref23 Smith (S2732494X22000213_ref33) 2017; 55 Lee (S2732494X22000213_ref13) 2015; 59 Tamma (S2732494X22000213_ref24) 2015; 60 Henderson (S2732494X22000213_ref25) 2021; 73 Maglio (S2732494X22000213_ref31) 2004; 48 Logan (S2732494X22000213_ref3) 2017; 215 Karaiskos (S2732494X22000213_ref21) 2020; 9 Lee (S2732494X22000213_ref12) 2013; 56 Gutiérrez-Gutiérrez (S2732494X22000213_ref20) 2019; 25 Ko (S2732494X22000213_ref18) 2018; 37 Benanti (S2732494X22000213_ref17) 2019; 63 Tamma (S2732494X22000213_ref22) S2732494X22000213_ref4 Andes (S2732494X22000213_ref28) 2005 Castanheira (S2732494X22000213_ref1) 2019; 6 S2732494X22000213_ref15 S2732494X22000213_ref16 Son (S2732494X22000213_ref10) 2018; 73 Dudley (S2732494X22000213_ref27) 2013; 56 Sfeir (S2732494X22000213_ref9) 2018; 52 Tamma (S2732494X22000213_ref19) 2017; 64 Harris (S2732494X22000213_ref8) 2018; 320 Gudiol (S2732494X22000213_ref7) 2017; 61 Gutiérrez-Gutiérrez (S2732494X22000213_ref6) 2016; 60 Rodríguez-Baño (S2732494X22000213_ref5) 2012; 54 Heil (S2732494X22000213_ref32) 2016; 54 Chopra (S2732494X22000213_ref11) 2012; 56 Reese (S2732494X22000213_ref30) 2005; 26 Wang (S2732494X22000213_ref14) 2016; 3 Patel (S2732494X22000213_ref34) 2019; 32 Diekema (S2732494X22000213_ref2) 2019; 63 |
| References_xml | – volume: 60 start-page: 4159 year: 2016 ident: S2732494X22000213_ref6 article-title: A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00365-16 contributor: fullname: Gutiérrez-Gutiérrez – volume: 60 start-page: 1319 year: 2015 ident: S2732494X22000213_ref24 article-title: Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia publication-title: Clin Infect Dis contributor: fullname: Tamma – volume: 58 start-page: 987 year: 2006 ident: S2732494X22000213_ref29 article-title: Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkl349 contributor: fullname: Roos – volume: 52 start-page: 554 year: 2018 ident: S2732494X22000213_ref9 article-title: Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2018.07.021 contributor: fullname: Sfeir – volume: 73 start-page: e3842 year: 2021 ident: S2732494X22000213_ref25 article-title: Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa1479 contributor: fullname: Henderson – volume: 73 start-page: 263 year: 2018 ident: S2732494X22000213_ref10 article-title: Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis publication-title: J Antimicrob Chemother doi: 10.1093/jac/dky168 contributor: fullname: Son – volume: 320 start-page: 984 year: 2018 ident: S2732494X22000213_ref8 article-title: Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance publication-title: JAMA doi: 10.1001/jama.2018.12163 contributor: fullname: Harris – volume: 26 start-page: 114 year: 2005 ident: S2732494X22000213_ref30 article-title: Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2005.06.004 contributor: fullname: Reese – ident: S2732494X22000213_ref16 – volume: 61 start-page: e00164 year: 2017 ident: S2732494X22000213_ref7 article-title: Efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in hematological patients with neutropenia publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00164-17 contributor: fullname: Gudiol – volume: 54 start-page: 167 year: 2012 ident: S2732494X22000213_ref5 publication-title: Clin Infect Dis doi: 10.1093/cid/cir790 contributor: fullname: Rodríguez-Baño – volume: 6 start-page: S23 year: 2019 ident: S2732494X22000213_ref1 article-title: Variations in the occurrence of resistance phenotypes and carbapenemase genes among Enterobacteriaceae isolates in 20 years of the SENTRY antimicrobial surveillance program publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofy347 contributor: fullname: Castanheira – volume: 59 start-page: 7558 year: 2015 ident: S2732494X22000213_ref13 article-title: Cefepime therapy for monomicrobial Enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01477-15 contributor: fullname: Lee – volume: 25 start-page: 932 year: 2019 ident: S2732494X22000213_ref20 article-title: Current options for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in different groups of patients publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2019.03.030 contributor: fullname: Gutiérrez-Gutiérrez – volume: 56 start-page: 1301 year: 2013 ident: S2732494X22000213_ref27 article-title: Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (break points) for Entero bacteriaceae and Pseudomonas aeruginosa: I publication-title: Cephalosporins and aztreonam. Clin Infect Dis doi: 10.1093/cid/cit017 contributor: fullname: Dudley – ident: S2732494X22000213_ref23 – volume: 56 start-page: 3936 year: 2012 ident: S2732494X22000213_ref11 article-title: Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.05419-11 contributor: fullname: Chopra – volume: 56 start-page: 488 year: 2013 ident: S2732494X22000213_ref12 article-title: Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum β-lactamase-producing Enterobacteriaceae: MIC matters publication-title: Clin Infect Dis doi: 10.1093/cid/cis916 contributor: fullname: Lee – volume: 63 year: 2019 ident: S2732494X22000213_ref2 article-title: The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00355-19 contributor: fullname: Diekema – ident: S2732494X22000213_ref15 – ident: S2732494X22000213_ref4 – volume: 32 start-page: 458 year: 2019 ident: S2732494X22000213_ref34 article-title: The role of cefepime in the treatment of extended-spectrum beta-lactamase infections publication-title: J Pharm Pract doi: 10.1177/0897190017743134 contributor: fullname: Patel – ident: S2732494X22000213_ref22 contributor: fullname: Tamma – volume: 3 start-page: ofw132 year: 2016 ident: S2732494X22000213_ref14 article-title: Cefepime therapy for cefepime-susceptible extended-spectrum β-lactamase-producing Enterobacteriaceae bacteremia publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofw132 contributor: fullname: Wang – volume: 215 start-page: S28 year: 2017 ident: S2732494X22000213_ref3 article-title: The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace publication-title: J Infect Dis doi: 10.1093/infdis/jiw282 contributor: fullname: Logan – volume: 9 start-page: 61 year: 2020 ident: S2732494X22000213_ref21 article-title: Carbapenem-sparing strategies for ESBL producers: when and how publication-title: Antibiotics (Basel) doi: 10.3390/antibiotics9020061 contributor: fullname: Karaiskos – volume: 63 start-page: e01813 year: 2019 ident: S2732494X22000213_ref17 article-title: Carbapenem versus cefepime or piperacillin-tazobactam for empiric treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in patients with hematologic malignancy publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01813-18 contributor: fullname: Benanti – volume: 48 start-page: 1941 year: 2004 ident: S2732494X22000213_ref31 article-title: Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.48.6.1941-1947.2004 contributor: fullname: Maglio – volume: 64 start-page: 972 year: 2017 ident: S2732494X22000213_ref19 article-title: The use of noncarbapenem β-lactams for the treatment of extended-spectrum β-lactamase infections publication-title: Clin Infect Dis doi: 10.1093/cid/cix034 contributor: fullname: Tamma – volume: 55 start-page: 470 year: 2017 ident: S2732494X22000213_ref33 article-title: Improved accuracy of cefepime susceptibility testing for extended-spectrum beta-lactamase-producing enterobacteriaceae with an on-demand digital dispensing method publication-title: J Clin Microbiol doi: 10.1128/JCM.02128-16 contributor: fullname: Smith – ident: S2732494X22000213_ref26 – volume: 37 start-page: 305 year: 2018 ident: S2732494X22000213_ref18 article-title: Appropriate noncarbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-017-3133-2 contributor: fullname: Ko – volume: 54 start-page: 840 year: 2016 ident: S2732494X22000213_ref32 article-title: Impact of CLSI break-point changes on microbiology laboratories and antimicrobial stewardship programs publication-title: J Clin Microbiol doi: 10.1128/JCM.02424-15 contributor: fullname: Heil – start-page: 10 year: 2005 ident: S2732494X22000213_ref28 article-title: Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2005.01265.x contributor: fullname: Andes |
| SSID | ssj0002810797 |
| Score | 2.2755768 |
| Snippet | To re-examine the use of noncarbapenems (NCBPs), specifically piperacillin-tazobactam (PTZ) and cefepime (FEP), for extended-spectrum beta-lactamase-producing... Abstract Objective: To re-examine the use of noncarbapenems (NCBPs), specifically piperacillin-tazobactam (PTZ) and cefepime (FEP), for extended-spectrum... Abstract Objective: To re-examine the use of noncarbapenems (NCBPs), specifically piperacillin-tazobactam (PTZ) and cefepime (FEP), for extended-spectrum... |
| SourceID | doaj pubmedcentral proquest crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e39 |
| SubjectTerms | Original |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV29jtQwELbgKiSE-CccICNdAYXBcbyxXXKwp6OhuAOJLrKdsVh0m0SbbEPFO9zL8Dw8CR57d7lFSDRISZPE8Sgzzvx45htCjgB0rVs-Y9G2l0zWLjBnAmfcG2yLw6VVWO98eq4-fNbv5giTs2v1hTlhGR44f7jXQbaaB4R15620Utngo1ymA3EOs-PD9RVn6msKGUW3xqhNQR5iRNsRtx6EeCXKPRWUkPr_Zl7-mSV5Re2c3Ca3NvYifZPpvEOuQXeX3MzBNppriO6RH2fAfsN20z5QDwGGxRJov6LDYoCV9RhY6dhkv8UV7Ce7pFNP22Q0jkDX8cRhuPswxN_fcqSLjm4j5CzVY67WS-pgsuwijY_Dfn6_HBJibNR_NKUXpHdjmAtGmnLisRYlzrXN-epG-uIMu_3M2fH5-5f3yaeT-ce3p2zTkoF5KdXELA_CK1nz6BfyYBzit5UGKqe9LLWNVFctcCeEL523GgCkN7WzRtYzkEZVD8hB13fwiFCvIERXeOZ420pTCxc1pfW6dX5WoT4tyNGWS82QkTeanJKmmsjMBpnZiLIgx8jB3SMIl50uRCFqNkLU_EuICvJ8y_8mLi_cM7Ed9OuxidZdNNqi2aYL8jDLw26qqq4wQ7MuiNqTlD1a9u90iy8JwtsgDr8Qj_8H8YfkBn6LHBd6Qg6iOMBTcn1s18_SovgFvmoVdg priority: 102 providerName: Directory of Open Access Journals |
| Title | Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI) |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36310806 https://www.proquest.com/docview/2730646438 https://pubmed.ncbi.nlm.nih.gov/PMC9615022 https://doaj.org/article/f4d80f16180d4a47afc0300300347221 |
| Volume | 2 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbYnpAQ4s3yqIzUAxy863Wc15GWrcoBhFqQuEW2M6FBzUOb7KWn_gf-DL-HX8KMk5Qu4oSUXJL4oczYMx5_85mxA4AkSnIZCvTttdCRLYRNCymkS-lYHKlNTPnOJ2fxx6_JuzXR5IRTLowH7TtbLuqLalGX5x5b2VZuOeHElp8-HKXEYq7UcsZm6BveWKJ_99EiXNGk8ZiLR_TQpqNdB6UWarVjfTxJ_788y78BkjcszvE9dnd0FfnboUv32S2oH7A7Q5yND-lDD9nPUxB_GLt5U3AHBbRlBbzZ8LZsYWMcxVRq0ZtLHLyuNxXvG557f7EDvsWbitHGQ4szX9XxsuZTcFz4VMzNtuIWeiMufHks9uvqR-vJYtH0cY8s8HVThAs67uHwlIaCbU1wr7rjr0_poJ-1ODx7_-YR-3K8_nx0IsbTGITTOu6FkYVysY4kLgllkVqiblulENjE6VVisNdBDtIq5VbWmQQAtEsja1IdhaDTOHjM9uqmhqeMuxgKXAWHVua5TiNl0Ugal-TWhQGZ0jk7mKSUtQPpRjag0eIMhZmRMDO1mrNDkuD1J8SU7R80m2_ZqC9ZofNEFnQsgMy10bEpHM5r_iKeTKzk1ST_DEcWbZeYGpptl6Fjh_4aemzJnD0Z9OG6qSAKCJwZzVm8oyk7fdl9g8rs2btH5X323yWfs9v0A4Y40Au2hzoAL9msy7f7PqKw78fDb-hSFss |
| link.rule.ids | 230,315,729,782,786,866,887,2108,4030,27934,27935,27936,53803,53805 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLVoWYCEeD-Gp5G6gIVnnMR5LWmZairaCrVFYhfZzg0ENQ9NZjas-Ad-hu_hS7jXSUoHsaqUbOI4tuJr34fPPWZsByCJklyGAm17JVRkCmHSQgppUzoWRyodU77z4jQ-_py8nxNNTjjmwjjQvjXltD6vpnX51WEr28rORpzY7OPRXkos5r4_22LXcb7K4JKT_s3Fi9CnSeMhG48IonVH-w6-P_W9Df3jaPr_Z1v-C5G8pHP271yxt3fZ7cHI5O_64nvsGtT32a0-Qsf7xKMH7NcJiL9c37wpuIUC2rIC3ix5W7aw1JaiMbVY6e847e1KV3zV8NxZmh3wNd5UjbYsWlwzq46XNR_D6sIlcS7XFTew0uLc1cdqv3_8bB3NLCpN7jAJ7tsUG4OOOyA9JbBgWyNQrO74mxM6Imgudk8P3j5kn_bnZ3sLMZzjIKxS8UpoWfg2VpFEZ1IWqSHSNy-FwCRWeYnGXgc5SOP71jNWJwCgbBoZnaooBJXGwSO2XTc1PGHcxlCg_xwamecqjXyD6lXbJDc2DEgJT9jOOLpZ29N1ZD2OLc5QCDISgsz3JmyXRv7iFeLYdg-a5ZdsGLusUHkiCzpQQOZKq1gXFldEdxHDJn7k9Sg3Gc5J2mjRNTTrLkOTEC09tPWSCXvcy9FFU0EUEKwzmrB4Q8I2-rJZgoLleL8HQXp65Zqv2I3F2dFhdnhw_OEZu0k_o48mPWfbKA_wgm11-fqlm01_AHrNK1o |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZokRASKs_C8jRSD3DwrjdxXkfa7qoVUFUtSNwi2xlDUPPQZvfSE_-BP8Pv4Zcw4-wuXcQJpOSS2LEVjz3j8TffMLYHkMZpISOBtr0SKjZOmMxJIW1GaXGk0gnFOx-dJyef0sMJ0eSsU3150L415bC-qIZ1-cVjK9vKjlY4sdHp-4OMWMyDYNQWbrTFruOcldGVjfpX7zPCfU2WLCPyiCRad3T2EATDYLyhgzxV_9_syz9hklf0zvT2f_T4DttZGpv8TV_kLrsG9T12q_fU8T4A6T77cQbiN-c3bxy34KAtK-DNjLdlCzNtyStTi7m-xOlv57ri84YX3uLsgC_wpmp0dNHi2ll1vKz5yr0ufDDnbFFxA3MtLnx9rPbz2_fW082i8uQem-C_TT4y6LgH1FMgC7a1AozVHX91RqmCJmL__Pj1A_ZxOvlwcCSW-RyEVSqZCy1dYBMVS9xUSpcZIn8bZxCa1KpxqrHXYQHSBIEdG6tTAFA2i43OVByBypJwl23XTQ2PGLcJONxHR0YWhcriwKCa1TYtjI1CUsYDtrca4bztaTvyHs-W5CgIOQlCHowHbJ9Gf12EuLb9g2b2OV-OX-5UkUpHiQVkobRKtLO4MvqLmDbxIy9XspPj3KQDF11Ds-hyNA3R4kObLx2wh70srZsK45DgnfGAJRtSttGXzTcoXJ7_eylMj_-55gt24_Rwmr87Pnn7hN2kf9E7lZ6ybRQHeMa2umLx3E-oX6GQLdo |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Re-evaluation+of+cefepime+or+piperacillin-tazobactam+to+decrease+use+of+carbapenems+in+extended-spectrum+beta-lactamase-producing+Enterobacterales+bloodstream+infections+%28REDUCE-BSI%29&rft.jtitle=Antimicrobial+stewardship+%26+healthcare+epidemiology+%3A+ASHE&rft.au=Vu%2C+Catherine+H&rft.au=Venugopalan%2C+Veena&rft.au=Santevecchi%2C+Barbara+A&rft.au=Voils%2C+Stacy+A&rft.date=2022&rft.issn=2732-494X&rft.eissn=2732-494X&rft.volume=2&rft.issue=1&rft.spage=e39&rft_id=info:doi/10.1017%2Fash.2022.21&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2732-494X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2732-494X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2732-494X&client=summon |